Si-Bone executive sells over $65k in company stock

SI-BONE, Inc. (NASDAQ:SIBN), a medical device company known for its surgical and medical instruments, has reported a notable transaction involving its President of Commercial Operations, Anthony J. Recupero. According to the latest filings, Recupero sold a total of 4,227 shares of company stock across two days, resulting in an aggregate sale of over $65,000.

The transactions took place on April 2nd and April 3rd, with shares being sold at varying prices. On the first day, Recupero sold 1,555 shares at an average price of $15.4909 and 1,752 shares at an average of $15.5159. These sales amounted to a total of approximately $51,272. The following day, an additional 920 shares were sold at an average price of $15.6298, totaling around $14,379. The sales were part of a pre-arranged trading plan under Rule 10b5-1, which allows insiders to sell shares at predetermined times to avoid accusations of trading on nonpublic information.

The transaction was not purely for liquidity purposes, as the sales on April 2nd were reported to cover tax withholding obligations related to the vesting of restricted stock units. This is a common practice for executives to satisfy tax liabilities without incurring out-of-pocket expenses.

Following the transactions, Recupero still holds a substantial number of shares in the company, with a disclosed ownership of 251,533 shares after the sales. This figure includes 167,475 shares issuable upon the settlement of restricted stock units granted to him.

Investors often monitor insider transactions as they can provide insights into an executive's view of the company's stock value and future performance. However, it's important to note that selling shares to cover tax obligations is a routine and often obligatory part of compensation for executives and does not necessarily indicate a lack of confidence in the company.

SI-BONE's stock performance and future prospects remain a focus for investors, and the company continues to be a player in the medical technology field with its innovative solutions for musculoskeletal conditions.

As investors assess the recent insider transactions at SI-BONE, Inc. (NASDAQ:SIBN), it's crucial to consider the company's financial health and market position. SI-BONE's current market capitalization stands at $632.39 million, indicating its size within the medical device sector. Despite the insider sales, SI-BONE holds a robust balance sheet, with cash reserves exceeding its debt, which is an encouraging sign for investors concerned about the company's financial stability.

One of the key InvestingPro Tips for SI-BONE highlights that the company does not pay a dividend, which could be a factor for income-focused investors to consider. Additionally, the company's shares are trading near their 52-week low, which could signal a potential entry point for value investors or indicate a need for caution if the market sentiment remains bearish.

Get The News You Want

Read market moving news with a personalized feed of stocks you care about.

Get The App

From a profitability standpoint, SI-BONE's performance over the last twelve months has been challenging, as analysts do not expect the company to be profitable this year. This is reflected in the negative P/E ratios, with the adjusted P/E ratio for the last twelve months as of Q4 2023 standing at -14.59. Despite this, SI-BONE has demonstrated strong revenue growth, with a 30.52% increase over the last twelve months as of Q4 2023.

For those considering a deeper dive into SI-BONE's financials and future outlook, there are additional InvestingPro Tips available, providing a comprehensive analysis of the company's performance and potential. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, giving you access to valuable insights that can inform your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.